Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies.
Varettoni M, Ferrari A, Frustaci AM, Ferretti VV, Rizzi R, Motta M, Piazza F, Merli M, Benevolo G, Visco C, Laurenti L, Ferrero S, Gentile M, Del Fabro V, Abbadessa A, Klersy C, Musto P, Fabbri N, Deodato M, Dogliotti I, Greco C, Corbingi A, Luminari S, Arcaini L.
Varettoni M, et al. Among authors: laurenti l.
Am J Hematol. 2020 Dec;95(12):1473-1478. doi: 10.1002/ajh.25961. Epub 2020 Sep 9.
Am J Hematol. 2020.
PMID: 32780514
Free article.
Clinical Trial.